SELLAS Life Sciences Group Inc. (SLS) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, SELLAS Life Sciences Group Inc. (NASDAQ: SLS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $9.68 (-4.68% 1D, market cap $1.95B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SLS ranks #499 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SLS carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -21.8%. By comparison, XERS (Xeris Biopharma Holdings Inc.) holds a C grade (64/100 RQD, P/E N/A, ROIC 16.0%, cap $1.95B) and SRPT (Sarepta Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $1.97B). Among the 5-stock peer group, SLS leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).
Per SLS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001390478), SELLAS Life Sciences Group Inc. generated $79.2M in revenue (-10.3% YoY), -$26.9M in net income, and -$28.4M in free cash flow against $78.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 56% of 52W Range • RSI-14 at 39.8 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While SLS currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.96) and Max Pain ($10.16) forces dealer call-delta covering toward $16.67.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
SELLAS Life Sciences Group Inc. (SLS) dropped -4.68% to $9.68, trading at 56% of its 52-week range ($1.75 – $15.88). Stretched risk/reward at current multiples (-22% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.
Barchart.com report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.
Stocktwits report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Singapore report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.
AstraZeneca emphasized ADC combinations, cell therapies and internally developed cancer vaccines as key oncology priorities.
Virginia Retirement Systems raised its stakes in all three stocks, with combined holdings worth nearly $3 million at September-end.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SLS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SLS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, SELLAS Life Sciences Group Inc. (SLS) ranks #499 by composite RQD confidence (38/100, grade D-) and #259 by equity capitalization ($1.95B). Within this direct 5-issuer industry benchmark cohort, SLS leads on earnings valuation at N/A trailing P/E, while XERS leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. XERS currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with SLS at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SLS
ACTIVE
SELLAS Life Sciences Group Inc. | D- | 38/100 | — | — | -21.8% | -4.68% | $1.95B | Benchmark Subject |
| XERS Xeris Biopharma Holdings Inc. | C | 64/100 | — | — | 16.0% | -0.37% | $1.95B | /xers-vs-sls → |
| SRPT Sarepta Therapeutics Inc. | E | 27/100 | — | 96.0% | -35.0% | -3.17% | $1.97B | /srpt-vs-sls → |
| BRVE Braveheart Bio Inc. | D | 46/100 | — | — | — | +1.51% | $1.94B | /brve-vs-sls → |
| TRVI Trevi Therapeutics Inc. | E | 30/100 | — | — | -23.7% | -1.81% | $1.93B | /trvi-vs-sls → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), SELLAS Life Sciences Group Inc. (SLS) reported GAAP revenue of $79.2M (-10.3% vs. FY2024 revenue of $88.2M , and -25.3% cumulative change since FY2023) , GAAP net income of -$26.9M, operating cash flow of -$28.4M, and free cash flow of -$28.4M (+19.8% YoY). On the balance sheet, SLS closed FY2025 with $78.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $79.2M | -$26.9M | -$28.4M | -$28.4M | $78.3M | — |
| FY2024 (FY) | 2024-12-31 | $88.2M | -$30.9M | -$35.4M | -$35.4M | $19.4M | — |
| FY2023 (FY) | 2023-12-31 | $106.0M | -$37.3M | -$31.4M | -$31.4M | — | — |
As of 2026-11-03, SELLAS Life Sciences Group Inc. (NASDAQ: SLS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $9.68 (-4.68% 1D, market cap $1.95B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SLS ranks #499 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SLS carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -21.8%. By comparison, XERS (Xeris Biopharma Holdings Inc.) holds a C grade (64/100 RQD, P/E N/A, ROIC 16.0%, cap $1.95B) and SRPT (Sarepta Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $1.97B). Among the 5-stock peer group, SLS leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).
Per SLS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001390478), SELLAS Life Sciences Group Inc. generated $79.2M in revenue (-10.3% YoY), -$26.9M in net income, and -$28.4M in free cash flow against $78.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
SLS last traded at $9.68 (-4.68% on volume of 6,262,245 shares), positioning the stock -19.06% below its 50-day simple moving average ($11.96) and +12.17% above its 200-day simple moving average ($8.63). Across its 52-week range of $1.75 to $15.88, SLS sits at the 56.1% percentile with a 14-day RSI of 39.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($8.47 to $10.89).
Why SLS Stock dropped -4.68% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-22% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, SLS scores 39 out of 100, earning a letter grade of D- and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
Overall, the sharpest valuation tradeoff is that a $2.05B market cap sits against reported losses and negative ROIC, so the stock's price relies on future outcomes not yet visible in the source financials. Upside drivers would need to come from improvements in cash generation; the 52-week range of $1.39 - $15.88 illustrates how wide the price swings have been. This brief is analytical and educational, not personalized financial advice.
SELLAS Life Sciences Group Inc. is a NASDAQ-listed issuer in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry, per the profile. Revenue is reported as $0.0M across the financial periods provided. Not available in source data for product details, customers, or revenue model.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-28.3M | $-26.9M | N/A | $-28.4M | $71.8M | N/A |
| FY 2024 | $0.0M | $-31.5M | $-30.9M | N/A | $-35.4M | $13.9M | N/A |
| FY 2023 | $0.0M | $-37.9M | $-37.3M | N/A | $-31.4M | N/A | N/A |
Per the SEC financials, reported revenue is $0.0M in each period and operating and net losses appear in all three years provided. Gross, operating, and net margins are each 0% per the market data. Per the market data, ROIC is -21.8%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Per the RQD rating, Debt/Equity is 0.5; the source data does not provide a debt figure in the SEC financials, so the balance sheet posture beyond these ratios is not fully resolved.
Per the recent news wire, the items include:
The news wire does not provide the underlying detail of these reports beyond headlines and summaries. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for SELLAS Life Sciences Group Inc. (SLS) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.
Barchart.com report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.
Stocktwits report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Singapore report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.
Welcome to the SLS (SELLAS Life Sciences Group Inc.) Roar Pit. Current RQD Composite is 39/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on SLS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless SELLAS Life Sciences Group Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on SLS, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $10.15 (52-wk range $1.39 - $15.88), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).